- Home
- ABUS vs HTD Comparison
ABUS vs HTD Comparison
Compare ABUS & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABUS | HTD |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.5M | 843.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABUS | HTD |
|---|---|---|
| Price | $4.84 | $23.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 92.3K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,606,000.00 | N/A |
| Revenue This Year | $125.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 116.64 | N/A |
| 52 Week Low | $2.71 | $16.17 |
| 52 Week High | $5.10 | $22.13 |
Technical Indicators
Market Signals| Indicator | ABUS | HTD |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 38.98 |
| Support Level | $4.65 | $23.30 |
| Resistance Level | $5.05 | $23.99 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 67.46 | 29.76 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.